Shenzhen HighTide Biopharmaceutical, Ltd.
Suite A228, NO. 19 Gaoxin C.1st Ave.,Nanshan Distr
Shenzhen
Guangdong
518057
China
Tel: 86-755-21534843
Fax: 86-755-21534843
Website: http://en.hightidebio.com/
Email: info@hightidebio.com
About Shenzhen HighTide Biopharmaceutical, Ltd.
Shenzhen HighTide Biopharmaceutical Ltd., a subsidiary of Shenzhen Hepalink Pharmaceutical Co., Ltd., was founded in 2011 with the focus to develop innovative peptide therapeutics for unmet medical needs including: diabetes and diabetic complications, antibiotic-resistant bacterial infections, cancers and other debilitating diseases.YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Liping Liu
7 articles about Shenzhen HighTide Biopharmaceutical, Ltd.
-
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
1/5/2023
HighTide Therapeutics Inc., a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital.
-
HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development
10/20/2022
HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
-
A roundup of last week's top clinical trial updates and news.
-
HighTide Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus
4/28/2022
HighTide Therapeutics, Inc. announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
-
HighTide to Present at the BofA Securities 2021 Health Care Conference
4/28/2021
HighTide Therapeutics, a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, announced that Company’s Management will provide a corporate presentation and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference to be held May 10-13, 2021.
-
HighTide Therapeutics to Present Phase 2 Results of HTD1801 in NASH Patients Co-Morbid with Type 2 Diabetes at NASH Summit
12/15/2020
HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk factors
-
Profil Institute for Clinical Research, Inc. And Shenzhen HighTide Biopharmaceutical Announce A Strategic Partnership Focused On The Development Of New Therapies For Diabetes And NAFLD/NASH
7/28/2016